Many women prefer chocolate over sex. Now scientists are … - Canada.com

September 5th, 2007

Many women prefer chocolate over sex. Now scientists are …Canada.com, Canada - 6 hours agoBasson contends that the reported prevalence of "hypoactive sexual disorder" in women of around 30 to 40 per cent may be wrong and misleading. …

Read full story

Testosterone Patch Benefits Women With Low Sexual Desire - Science Daily (press release)

September 3rd, 2007

Testosterone Patch Benefits Women With Low Sexual DesireScience Daily (press release) - Aug 14, 2007… The Journal of Sexual Medicine supports the claim that women with hypoactive sexual desire disorder or HSDD (persistent or recurrent deficiency and/or …

Read full story

Women Call Improved Libido With Testosterone Patch a Meaningful … - MedPage Today

September 3rd, 2007

Women Call Improved Libido With Testosterone Patch a Meaningful …MedPage Today, NJ - Aug 15, 200715 — For women with hypoactive sexual desire disorder following surgical menopause, low doses of testosterone delivered by an investigational transdermal …

Read full story

Oppenheimer Starts BioSante at 'Buy' - Forbes

September 3rd, 2007

Oppenheimer Starts BioSante at 'Buy'Forbes, NY - Aug 23, 2007… saying he is optimistic that LibiGel, the company's testosterone gel for female hypoactive sexual desire disorder, will generate income in the next 12 …

Read full story

• About 52 percent of women using sex-drive patch report improvement - The Plain Dealer - cleveland.com

September 3rd, 2007

• About 52 percent of women using sex-drive patch report improvementThe Plain Dealer - cleveland.com, OH - Aug 21, 2007Low sex drive - known clinically as hypoactive sexual desire disorder - can be a consequence of menopause. The study is actually a subset of a larger …

Read full story

VIVUS To Present at the Noble Financial Conference - PharmaLive.com (press release)

August 16th, 2007

VIVUS To Present at the Noble Financial ConferencePharmaLive.com (press release), PA - Aug 15, 2007… Testosterone MDTS(R), for which a phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, …

Read full story

Vivus gets $140M milestone - MSN Money

August 16th, 2007

Vivus gets $140M milestoneMSN Money - Aug 9, 2007The Mountain View company is still developing drugs to treat obesity, erectile dysfunction and hypoactive sexual desire disorder.

Read full story

Testosterone patch aids women's sex desire - United Press International

August 16th, 2007

SpiritIndiaTestosterone patch aids women's sex desireUnited Press International - 21 hours ago15 (UPI) — A US study of women with hypoactive sexual desire disorder, or lack of sexual interest, showed improved sexual desire following testosterone …Testosterone Patch Benefits Women With Low Sexual Desire Science Daily (press release)Women Call Improved Libido With Testosterone Patch a Meaningful … MedPage Todayall 15 news articles

Read full story

VIVUS Reports Second Quarter 2007 Financial Results and … - Business Wire (press release)

August 2nd, 2007

VIVUS Reports Second Quarter 2007 Financial Results and …Business Wire (press release), CA - 20 hours ago… Testosterone MDTS®, for which a phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, …

Read full story

KV Pharmaceutical Announces US Food and Drug Administration … - CNNMoney.com

August 2nd, 2007

KV Pharmaceutical Announces US Food and Drug Administration …CNNMoney.com - Jul 30, 2007… Testosterone MDTS(R), for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, …

Read full story

Vivus Gains Evamist Approval, $140M Payment From Partner - BioWorld Online

July 31st, 2007

Vivus Gains Evamist Approval, $140M Payment From PartnerBioWorld Online, GA - 10 hours agoThe company also plans to find a partner for its testosterone-based spray product for treating hypoactive sexual desire disorder, or low sexual desire in …

Read full story

VIVUS Receives FDA Approval of Evamist NDA - Business Wire (press release)

July 30th, 2007

VIVUS Receives FDA Approval of Evamist NDABusiness Wire (press release), CA - 1 hour ago… Testosterone MDTS ® , for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, …

Read full story

Viagra nation - Times Online

July 15th, 2007

Viagra nationTimes Online, UK - 3 hours agoThe condition of hypoactive sexual-desire disorder has been invented to give low libido the correct, respectable veneer in the face of studies indicating …

Read full story

VIVUS Announces Abstract Published at American Diabetes … - Genetic Engineering News (press release)

July 9th, 2007

VIVUS Announces Abstract Published at American Diabetes …Genetic Engineering News (press release), NY - Jun 25, 2007… Testosterone MDTS(R), for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); EvaMist(TM), …

Read full story

Research and Markets: A Third of Patients Remain Refractory to … - Genetic Engineering News (press release)

June 30th, 2007

Research and Markets: A Third of Patients Remain Refractory to …Genetic Engineering News (press release), NY - Jun 26, 2007Prescription and treatment trends among important subcategories of female sexual dysfunction, such as hypoactive sexual desire disorder (HSDD). …

Read full story

VIVUS Announces Abstract Published at American Diabetes … - PharmaLive.com (press release)

June 28th, 2007

VIVUS Announces Abstract Published at American Diabetes …PharmaLive.com (press release), PA - Jun 25, 2007… Testosterone MDTS(R), for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); EvaMist(TM), …

Read full story

A streetcar named indifference - WorldNetDaily

June 27th, 2007

A streetcar named indifferenceWorldNetDaily, OR - 7 hours agoThe study will help evaluate an investigational medication for a condition called Hypoactive Sexual Desire Disorder (HSSD). …" Visit or call . …

Read full story

Research and Markets: A Third of Patients Remain Refractory to … - Business Wire (press release)

June 27th, 2007

Research and Markets: A Third of Patients Remain Refractory to …Business Wire (press release), CA - 11 hours agoPrescription and treatment trends among important subcategories of female sexual dysfunction, such as hypoactive sexual desire disorder (HSDD). …

Read full story